Anti-CD44 monoclonal antibody (IM7) induces murine systemic shock mediated by platelet activating factor

Journal of Autoimmunity

Volumn 18, Issue 1, 2002, Pages 9-15

  Tanaka, Yasuo ^a   Makiyama, Yasushi ^a   Mitsui, Youji ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Autoimmune diseases; CD44; Immunotherapy; Platelet activating factor; Shock

Indexed keywords

CYPROHEPTADINE; DIPHENHYDRAMINE; HERMES ANTIGEN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G2B; ISRAPAFANT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IM 7; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE MONITORING; BLOOD VESSEL PERMEABILITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; HEMATOCRIT; HYPOTENSION; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHOCK; TREATMENT OUTCOME;

EID: 0037006433     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2001.0559     Document Type: Article

References (45)

1. CD44 structure and function
2. Requirement for CD44 in activated T cell extravasation into an inflammatory site
3. The normal structure and function of CD44 and its role in neoplasia
4. The CD44 protein family
5. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia
6. CD44: One ligand, two functions
7. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis
8. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody
9. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment
10. Monoclonal antibodies against the CD44 [In(Lu)-related p80], and Pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors
11. Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues
12. T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14
13. 2 fragments
14. Quantitative evaluation of passive cutaneous anaphylaxis (PCA) using a hand-held spectrophotometer
15. A novel method for induction and detection of anaphylactic reaction using the mouse abdominal wall (AW method)
16. Pharmacological characterization of mouse ear PCA
17. Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat
18. Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat
19. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils
20. Pharmacological actions of Y-24180: I. A potent and specific antagonist of platelet-activating factor
21. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: Evidence for a platelet independent mechanism
22. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats
23. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice
24. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids
25. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids
26. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
27. CD16 cross-linking induces both secretory and extracellular signal-regulated kinase (ERK)-dependent cytosolic phospholipase A2 (PLA2) activity in human natural killer cells: Involvement of ERK, but not PLA2, in CD16-triggered granule exocytosis
28. Analysis of CD44-containing lipid rafts: Recruitment of annexin II and stabilization by the actin cytoskeleton
29. Suppressive effects of antihistaminic and/or anti-PAF agents on passive anaphylactic shock in mice sensitized with allogeneic monoclonal IgE and IgG1 antibodies and hyperimmune serum
30. Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16)
31. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist
32. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase
33. CD44H participates in the intrahepatic growth of murine colon 26 adenocarcinoma cells
34. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody
35. Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide
36. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody
37. CD44 involvement in experimental collagen-induced arthritis (CIA)
38. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells
39. Effects of ginkgolide B, a platelet-activating factor inhibitor on insulitis in the spontaneously diabetic BB rat
40. An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats
41. A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice
42. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis
43. Production, metabolism and effect of platelet-activating factor on the growth of the human K562 erythroid cell line
44. Augmentation of tumor metastasis by platelet-activating factor